Gundogan, B. D. Et Al. 2021. Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations. Journal of clinical research in pediatric endocrinology , vol.13 , 342-346.

Gundogan, B. D., Sagcan, F., Bozdogan, S., Balci, Y., Daloglu, F. T., & Citak, E. C., (2021). Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations. Journal of clinical research in pediatric endocrinology , vol.13, 342-346.

Gundogan, Begumhan Et Al. "Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations," Journal of clinical research in pediatric endocrinology , vol.13, 342-346, 2021

Gundogan, Begumhan D. Et Al. "Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations." Journal of clinical research in pediatric endocrinology , vol.13, pp.342-346, 2021

Gundogan, B. D. Et Al. (2021) . "Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations." Journal of clinical research in pediatric endocrinology , vol.13, pp.342-346.

@article{article, author={Begumhan Demir Gundogan Et Al. }, title={Vandetanib in a child affected by neurofibromatosis type 1 and medullary thyroid carcinoma with both NF1 and homozygous RET proto-oncogen germ-line mutations}, journal={Journal of clinical research in pediatric endocrinology}, year=2021, pages={342-346} }